BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 17 October 1996
The company's studies, conducted at an independent testing laboratory as well as at a major university, show that latex gloves exposed to fluid and mechanical stress similar to conditions encountered in surgery allowed the passage of viruses and bacteria in 10-30 percent of the latex gloves tested within a one-hour testing period.
Gloves that are permeable to microorganisms expose patients and health-care professionals to potential infectious diseases, including HIV and Hepatitis B and C. Use of surgical latex gloves is the standard of care in more than 26 million surgeries per year in the United States.
"The company believes that latex gloves will remain the industry standard and provide the best protection available for most health-care providers and patients," said M. Lee Helsebus, MEDD chairman and CEO. "Knowing when latex has lost its protective capabilities can be critical to the health of patients and health-care providers. With the adoption of a continuous latex glove monitoring system, used in conjunction with a glove-changing protocol, latex gloves can be made a more effective infection barrier."
Medical Device Technologies believes that its own investigations, as well as independent reports published in recent medical literature, demonstrate the need for devices, such as the company's electronic Fluid Alarm System (FAS), that monitor the integrity of infection barriers such as surgical latex gloves. The company is continuing its scientific investigation and will provide data when complete to glove manufacturers and regulatory agencies.
Medical Device Technologies develops, manufactures and markets specialty medical devices. The company markets the Fluid Alarm System, a device for monitoring the breakdown of infection barriers between a patient and health-care professional.
Currently, the company is developing two additional medical devices: the Cell Recovery System (CRS), a noninvasive medical device for endoscopic cell recovery and diagnosis, for which the company recently received marketing clearance from the FDA; and the Intracranial Pressure Monitoring System (ICP), a diagnostic device for detecting pressure within the skull noninvasively, for which the company is seeking marketing clearance from the FDA.
-0-
NOTE: This news release contains forward-looking statements regarding the company and its systems. These forward-looking statements are based largely on the company's expectations and are subject to a number of risks and uncertainties, certain of which are beyond the company's control.
Actual results could vary materially from those expected due to a variety of factors, including the uncertainty of further studies, the uncertainty of successful completion of preclinical and clinical trials, anticipated market for and sales of the company's products, and anticipated receipt of FDA approval and the timing of such receipt for certain of the company's systems.
The company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
--30--CB/np* RPL/la EW/la
CONTACT: Medical Device Technologies Inc., San Diego Virginia Rybski, 619/236-1332
REPEATS: New York 212-752-9600 or 800-221-2462; Boston 617-236-4266 or 800-225-2030; SF 415-986-4422 or 800-227-0845; LA 310-820-9473 Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com
Copyright (c) 1996/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
961017
BW961021
Copyright © 1996 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .